Announcements Trials
Browse Landscape

Phase

Phase 2 91Phase 1 24Phase 3 17Phase 1/2 13Phase 4 3Phase EARLY_PHASE1 2Phase 2/3 2Phase NA 1

Status

Active not recruiting 2

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Prednisone 5Androgen Antagonists 5gallium 68 PSMA-11 4enzalutamide 3bicalutamide 3Triptorelin Pamoate 3Radiosurgery 3Leuprolide 3Goserelin 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Zoledronic Acid 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Mitoxantrone 2Flutamide 2Celecoxib 2Abiraterone Acetate 2satraplatin 1relugolix 1pertuzumab 1nilutamide 1maltodextrin 1luprolide acetate gel depot 1histrelin 1genistein combined polysaccharide 1fluciclovine F-18 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Prostatic Neoplasms × Abiraterone Acetate × Clear all
NCT03706365 2026-04-24

CYCLONE 2

Eli Lilly and Company

Phase 2/3 Active not recruiting
393 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting
11,992 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡